Recent insider trends for Genocea Biosciences, Inc. (NASDAQ:GNCA) have caught the attention of investors. Analysts monitor insider data to understand the sentiment of a company’s largest and most important shareholders. GNCA’s insider trading patterns have some implications for where the stock might be headed.
Institutions own 12.01% of Genocea Biosciences, Inc. (GNCA)’s shares. The total value of these holdings, in millions, is $9. Among active positions in the latest quarter, 28 holders increased their positions by a total of 570933 shares, 28 holders decreased the positions by a total of 7.36 million shares, and 15 holders held their positions. This works out to a net decrease in ownership of 6.79 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 11 holders initiated new positions by a total of 371919 shares and 11 holders exited their positions by a total of 3.86 million shares. This nets out to a decrease of 3.49 million shares and is another bearish sign for GNCA.
In the last three months, insiders executed a total of 1 trades. 1 of these were buys. Insider ownership increased by a total of 25000 shares, which suggests that GNCA’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 4 buys and 3 sells, and ownership increased by a net of 55366 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Genocea Biosciences, Inc. (NASDAQ:GNCA)’s short interest is 2.87 million shares, or 12.66% of the float. This represents an increase of 74% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Ownership trends and trading patterns can be useful tools for predicting a stock’s performance, but it’s also important to consider the technicals in order to form a more comprehensive view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that GNCA is a Weak sell, which implies that GNCA is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Genocea Biosciences, Inc. (NASDAQ:GNCA) is overvalued.